Navigation Links
Reportlinker Adds Companion Diagnostics Partnering Terms and Agreements
Date:4/14/2011

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Companion Diagnostics Partnering Terms and Agreements

http://www.reportlinker.com/p0362248/Companion-Diagnostics-Partnering-Terms-and-Agreements.html

Summary

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in companion diagnostics partnering deals

• Deal term analysis

• Companion diagnostics partnering agreement structure

• Companion diagnostics partnering contract documents

• Top companion diagnostics deals by value

• Most active companion diagnostics dealmakers

• Average companion diagnostics deal values

Description

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual companion diagnostics deals. In addition contract documents as submitted to the Securities Exchange Commission by companies and their partners are available where they have been disclosed. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of companion diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostics dealmaking since 2005.

Chapter 3 provides a review of the leading companion diagnostics deals since 2005. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of companion diagnostics deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2005, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostics partnering and dealmaking since 2005.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostics technologies and products.

Key benefits

Companion Diagnostics Partnering Terms and Agreements provides the reader with the following Key benefits:

• In-depth understanding of companion diagnostics deal trends since 2005

• Analysis of the structure of companion diagnostics agreements with numerous real life case studies

• Comprehensive access to over 500 actual companion diagnostics deals entered into by the world's biopharma companies

• Detailed access to actual companion diagnostics deals and contracts enter into by the leading fifty bigpharma companies

• Understand the key deal terms companies have agreed in previous deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide.

Companion Diagnostics Partnering Terms and Agreements includes:

• Trends in companion diagnostics dealmaking in the biopharma industry since 2005

• Analysis of companion diagnostics deal structure

• Links to online access to over 500 companion diagnostics deals

• The leading companion diagnostics deals by value since 2005

• Most active companion diagnostics dealmakers since 2005

• The leading companion diagnostics partnering resources

In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by:

• Company A-Z

• Headline value

• Stage of development at signing

• Deal component type

• Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive links to online access to over 500 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise companion diagnostics rights granted or optioned?

• What is actually granted by the agreement to the partner company?

• What exclusivity is granted?

• What is the payment structure for the deal?

• How are sales and payments audited?

• What is the deal term?

• How are the key terms of the agreement defined?

• How are IPRs handled and owned?

• Who is responsible for commercialization?

• Who is responsible for development, supply, and manufacture?

• How is confidentiality and publication managed?

• How are disputes to be resolved?

• Under what conditions can the deal be terminated?

• What happens when there is a change of ownership?

• What sublicensing and subcontracting provisions have been agreed?

• Which boilerplate clauses does the company insist upon?

• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

• Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in companion diagnostics dealmaking

* 2.1. Introduction

* 2.2. Companion diagnostics partnering over the years

* 2.3. Bigpharma companion diagnostics dealmaking activity

* 2.4. Bigpharma not active in companion diagnostics

* 2.5. Companion diagnostics partnering by deal type

* 2.6. Companion diagnostics partnering by disease type

* 2.7 Average deal terms for companion diagnostics

* 2.7.1 - 2.6. Companion diagnostics headline values

* 2.7.2 - 2.6. Companion diagnostics upfront payments

* 2.7.3 - 2.6. Companion diagnostics milestone payments

* 2.7.4 - 2.6. Companion diagnostics royalty rate

Chapter 3 – Leading companion diagnostics deals

* 3.1. Introduction

* 3.2. Top companion diagnostics deals by value

* 3.3. Top companion diagnostics deals involving bigpharma

Chapter 4 – Bigpharma companion diagnostics deals

* 4.1. Introduction

* 4.2. How to use bigpharma companion diagnostics partnering deals

* 4.3. Bigpharma companion diagnostics partnering company profiles

* Abbott

* Actavis

* Alcon Labs

* Allergan

* Amgen

* Apotex

* Astellas

* AstraZeneca

* Baxter International

* Bayer

* Biogen Idec

* Boehringer Ingelheim

* Bristol-Myers Squibb

* Celgene

* Cephalon

* Chugai

* CSL

* Daiichi Sankyo

* Dainippon Sumitomo

* Eisai

* Eli Lilly

* Forest Laboratories

* Genzyme

* Gilead Sciences

* GlaxoSmithKline

* Hospira

* Johnson & Johnson

* Kyowa Hakko Kirin

* Lundbeck

* Meda

* Menarini

* Merck & Co

* Merck KGaA

* Mitsubishi Tanabe

* Mylan

* Novartis

* Novo Nordisk

* Nycomed Pharma

* Otsuka

* Pfizer

* Ratiopharm

* Roche

* Sanofi-Aventis

* Servier

* Shionogi

* Shire

* Takeda

* Teva

* UCB

* Watson

Chapter 5 – Companion diagnostics dealmaking directory

* 5.1. Introduction

* 5.2. Company A-Z

* 5.3. By stage of development

* Discovery

* Pre-clinical

* Phase I

* Phase II

* Phase III

* Registration

* Marketed

* 5.4. By deal type

* Asset and product purchase

* Collaborative R&D

* Co-development

* Co-marketing

* Co-promotion

* Development

* Distribution

* Evaluation

* Joint venture

* Licensing

* Manufacturing

* Marketing

* Option

* Promotion

* Research

* Supply

* 5.5. By therapy area

* Hospital care

* Cardiovascular

* Central nervous system

* Dental

* Dermatology

* Gastrointestinal

* Genetic disorders

* Genitourinary

* Hematology

* Genetic disorders

* Immunology

* Infection

* Inflammatory

* Metabolic

* Musculoskeletal

* Oncology

* Ophthalmics

* Respiratory

* Sensory organ

* Animal health

Chapter 6 – Companion diagnostics partnering resource centre

* 6.1. Online companion diagnostics partnering

* 6.2. Companion diagnostics partnering events

* 6.3. Further reading on companion diagnostics dealmaking

Appendices

* Appendix 1 – Deal type definitions

* Appendix 2 – Example companion diagnostics partnering agreement

* About Wildwood Ventures

Figures in report

* Figure 1: Biomarker partnering since 2005

* Figure 2: Bigpharma – top 50 – biomarker deals 2005 to 2010

* Figure 3: Inactive bigpharma in biomarkers 2005-2010

* Figure 4: Biomarker partnering by deal type since 2005

* Figure 5: Biomarker partnering by disease type since 2005

* Figure 6: Biomarker partnering by oncology target since 2005

* Figure 7: Biomarker deals with a headline value

* Figure 8: Biomarker deal headline value distribution, US$million

* Figure 9: Biomarker deal headline value distribution, US$million

* Figure 10: Biomarker deals with upfront payment values

* Figure 11: Biomarker deal upfront payment distribution, US$million

* Figure 12: Biomarker deals with milestone payments

* Figure 13: Biomarker deal milestone payment distribution, US$million

* Figure 14: Biomarker deals with royalty rates, %

* Figure 15: Biomarker deal royalty rate distribution, %

* Figure 16: Top biomarker deals by value since 2005

* Figure 17: Top biomarker deals signed by bigpharma value since 2005

* Figure 18: Online partnering resources

* Figure 19: Forthcoming partnering events

* Figure 20: Deal type definitions

* Figure 21: Companion diagnostics partnering agreement between Roche, Rules-Based Medicine and Psynova Neurotech, December 2009

To order this report:

Companion Diagnostics Partnering Terms and Agreements

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds ENT Devices Market Outlook in China to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
2. Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
3. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
4. Reportlinker Adds Arthritis Therapy Area Pipeline Report
5. Reportlinker Adds Bronchitis Therapy Area Pipeline Report
6. Reportlinker Adds Neuropathy Therapy Area Pipeline Report
7. Reportlinker Adds Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
10. Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report
11. Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: 2015-2019" ... market for blood monitoring & cardiac monitoring devices was valued at ... 24,830.1 million by 2019 at a CAGR of 6.8% from 2015 ... Europe , Asia-Pacific , Latin ... Africa . The three major factors determining growth of the ...
(Date:2/9/2016)... , Feb. 9, 2016  Increasingly, health care ... their vital signs with wireless technology. With the Vios ... automate patient oversight and remotely detect problems before they ... signs across in-hospital environments. the United ... United States . --> The ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson (NYSE: ... Markets Global Healthcare Conference on Tuesday, Feb. 23, at ... Dominic Caruso , Vice President, Finance & Chief Financial ... will represent the Company in a session scheduled at ... --> www.investor.jnj.com . --> This ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... The recreational use of marijuana has been legal in Colorado ... lot of restrictions as to where they can smoke pot. , As ... cannabis “may not be consumed openly or publicly.” , Given the momentum of the ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... staff helped give free oral screenings to 150 children in kindergarten through third ... The College of Dental Medicine joined Chinese American Dental Society of Southern California ...
(Date:2/10/2016)... TN (PRWEB) , ... February 09, 2016 , ... ... to sports concussion, yet the cause of injury may be one of many ... two-day advanced PT Continuing Education Course , Mastering Rehab Solutions for ...
(Date:2/9/2016)... ... 09, 2016 , ... Center for Autism and Related Disorders ... spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering autism treatment in ... key to providing effective treatment for individuals with ASD. Now, over 1,800 low-income ...
(Date:2/9/2016)... ... 2016 , ... URise Products announces today an Indiegogo campaign ... Walker. Made entirely in the USA, the StandUp Walker is one of the ... novel patent-pending design offers 2-in-1 benefits of a stand-assist device combined with ...
Breaking Medicine News(10 mins):